Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jun 15, 2023; 15(6): 1096-1104
Published online Jun 15, 2023. doi: 10.4251/wjgo.v15.i6.1096
Advanced gastric cancer achieving major pathologic regression after chemoimmunotherapy combined with hypofractionated radiotherapy: A case report
Meng-Long Zhou, Ruo-Ne Xu, Cong Tan, Zhen Zhang, Jue-Feng Wan
Meng-Long Zhou, Ruo-Ne Xu, Zhen Zhang, Jue-Feng Wan, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
Meng-Long Zhou, Ruo-Ne Xu, Cong Tan, Zhen Zhang, Jue-Feng Wan, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
Meng-Long Zhou, Ruo-Ne Xu, Zhen Zhang, Jue-Feng Wan, Shanghai Key Laboratory of Radiation Oncology, Fudan University, Shanghai 200032, China
Cong Tan, Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
Author contributions: Zhou ML and Xu RN collected the pathological, biological, and clinical data; Zhou ML drafted the initial manuscript; Tan C reviewed the pathological results; Wan JF and Zhang Z reviewed or revised the manuscript and approved the final version; Wan JF had full access to all data and had final responsibility for the decision to submit for publication; and all authors contributed to the article and approved the submitted version.
Supported by the National Natural Science Foundation of China (General Program), No. 81773357.
Informed consent statement: Written informed consent was obtained from the patient for the publication of this manuscript and all accompanying images.
Conflict-of-interest statement: There is no potential conflicts of interest were disclosed.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jue-Feng Wan, MD, Assistant Professor, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, No. 270 Dong’ an Road, Shanghai 200032, China. wjf62313172@163.com
Received: February 19, 2023
Peer-review started: February 19, 2023
First decision: March 22, 2023
Revised: April 9, 2023
Accepted: April 23, 2023
Article in press: April 23, 2023
Published online: June 15, 2023
Processing time: 116 Days and 1.9 Hours
Core Tip

Core Tip: This case report describes a patient with unresectable advanced gastric cancer who received comprehensive treatment including chemoimmunotherapy and hypofractionated radiotherapy that was applied to treat the primary lesion; satisfactory efficacy was achieved. The combination of radiotherapy and immunotherapy is worthy of further exploration, and the dose division of radiotherapy is an important factor. Hypofractionated radiotherapy, compared to conventional fractionated radiotherapy, may better coordinate with immunotherapy.